(19)
(11) EP 2 776 013 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
30.08.2023 Bulletin 2023/35

(45) Mention of the grant of the patent:
26.07.2023 Bulletin 2023/30

(21) Application number: 12847165.3

(22) Date of filing: 08.11.2012
(51) International Patent Classification (IPC): 
A61K 9/127(2006.01)
 A61K 9/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 9/0009; A61K 9/1271; Y02A 50/30
(86) International application number:
PCT/US2012/064087
(87) International publication number:
WO 2013/070872 (16.05.2013 Gazette 2013/20)

(54)

METHODS AND COMPOSITIONS FOR X-RAY INDUCED RELEASE FROM PH SENSITIVE LIPOSOMES

VERFAHREN UND ZUSAMMENSETZUNGEN ZUR RÖNTGENINDUZIERTEN FREISETZUNG PH-EMPFINDLICHER LIPOSOME

PROCÉDÉS ET COMPOSITIONS POUR LA LIBÉRATION INDUITE PAR RAYONS X DE LIPOSOMES SENSIBLES AU PH

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 08.11.2011 US 201161556936 P

(43) Date of publication of application:
17.09.2014 Bulletin 2014/38

(73) Proprietors:
  • The Board of Trustees of the University of Arkansas
    Little Rock, AR 72207 (US)
  • BioVentures, LLC
    Little Rock, AR 72205-7199 (US)

(72) Inventors:
  • FOLOGEA, Daniel
    Boise, ID 83706 (US)
  • HENRY, Ralph
    Fayetteville, AR 72701 (US)
  • SALAMO, Greg
    Fayetteville, AR 72701 (US)
  • MAZUR, Yuriy
    Fayetteville, AR 72701 (US)
  • BORRELLI, Michael, J.
    Little Rock, AR 72205 (US)

(74) Representative: Mewburn Ellis LLP 
Aurora Building Counterslip
Bristol BS1 6BX
Bristol BS1 6BX (GB)


(56) References cited: : 
EP-A1- 0 312 212
WO-A1-2010/129686
US-A- 5 891 465
US-A1- 2006 159 739
 EP-A1- 2 255 790
US-A- 5 770 222
US-A1- 2006 099 141
US-A1- 2011 105 995
   
  • CORY J. HITZMAN ET AL: "Development of a respirable, sustained release microcarrier for 5-fluorouracil II:In vitro andin vivo optimization of lipid coated nanoparticles", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 95, no. 5, 1 May 2006 (2006-05-01), pages 1127-1143, XP055183263, ISSN: 0022-3549, DOI: 10.1002/jps.20590
  • ROSENTHAL D J ET AL: "A phase I study of SPI-077 (Stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer", INVESTIGATIONAL NEW DRUGS, MARTINUS NIJHOFF PUBLISHERS, BOSTON, US, vol. 20, no. 3, 1 August 2002 (2002-08-01) , pages 343-349, XP002546528, ISSN: 0167-6997, DOI: 10.1023/A:1016201732368 [retrieved on 2004-11-02]
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).